Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes

Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes

Triple negative breast cancers (TNBCs) are characterized by worse prognosis, higher propensity to earlier metastases, and shorter survival after recurrence compared with other breast cancer subtypes. Anthracycline- and taxane-based chemotherapy is still the mainstay of treatment in early stages, alt...

Full description

Bibliographic Details
Main Authors: Anna Diana, Francesca Carlino, Elisena Franzese, Olga Oikonomidou, Carmen Criscitiello, Ferdinando De Vita, Fortunato Ciardiello, Michele Orditura
Format: Article
Language:English
Published: MDPI AG 2020-03-01
Series:Cancers
Subjects:
triple negative breast cancer
neo-(adjuvant)
biomarkers
PARP inhibitors
immunotherapy
Online Access:https://www.mdpi.com/2072-6694/12/4/819

Internet

https://www.mdpi.com/2072-6694/12/4/819

Similar Items